Drug profile · INN
beclomethasone dipropionate
ORBEC
beclomethasone dipropionate (ORBEC) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: nasal. Current US regulatory status: approved.
Drug details — beclomethasone dipropionate
- US status
- approved
- Class
- —
- Route
- NASAL
- Patents
- 1
- Programs
- 19
- Data quality
- 0.89
Quick answer
beclomethasone dipropionate (ORBEC) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is beclomethasone dipropionate?
beclomethasone dipropionate (ORBEC) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for beclomethasone dipropionate?
ORBEC is a marketed brand name for beclomethasone dipropionate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of beclomethasone dipropionate?
beclomethasone dipropionate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.